

26<sup>th</sup> October, 2020

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

## Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and half year ended $30^{th}$ September, 2020

The presentation on unaudited Consolidated Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2020 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL VP (LEGAL) & COMPANY SECRETARY

Encl: A/a



Q2 FY 2020-21

Revenues: Summary



## **Revenue: Summary**

Revenues (Rs crores)	Q2 FY21	Q2 FY20	Gr%	H1 FY21	H1 FY20	Gr%
India	963	899	7%	1,888	1,806	5%
United States	327	380	-14%	700	757	-8%
Germany	261	250	4%	507	512	-1%
Brazil	129	156	-18%	268	330	-19%
Other countries	200	194	3%	434	370	17%
Others (Inc. CRAMS)	139	126	10%	276	252	9%
Total	2,017	2,005	1%	4,073	4,027	1%

